Zevra Therapeutics (ZVRA) Q3 2025 Earnings

Yes. Zevra Therapeutics reported Q3 2025 earnings of $-0.01 a share on Nov 5, 2025, beating the $-0.02 consensus estimate by 50.0%. Revenue was $26.1M against a $26.6M estimate.

Zevra Therapeutics posted a mixed but largely encouraging third quarter, nearly reaching breakeven as its rare disease franchise scaled with striking speed. The company reported a loss of just $0.01 per share for Q3 2025, clearing the $0.02 consensus estimate by 50.00%, even as revenue of $26.06 million came in fractionally below the $26.64 million analyst expectation, a miss of 2.17%. The headline figure nonetheless represented a 605.4% surge from the year-ago period, with MIPLYFFA, its treatment for Niemann-Pick disease type C, generating $22.40 million in net revenue as cumulative patient enrollments reached 137 since launch. A $1.20 million Medicare Part D gross-to-net adjustment tempered results modestly, but operating expenses fell to $20.37 million from $27.15 million a year ago, driven by lower R&D spending following the completion of a Phase 2 trial. Analysts trimmed forward estimates following the report, though consensus price targets held steady, suggesting the revenue shortfall was viewed as a near-term rather than structural concern. With $230.40 million in cash and the EMA reviewing arimoclomol for European approval, management expressed confidence in executing its rare disease strategy without tapping capital markets.